Remix heads to AACR with a 43% ORR already in hand for REM-422 in ACC
Remix Therapeutics will give a corporate update on its oral MYB mRNA degrader at AACR, building on a disclosed 3-of-7 response rate in a disease with no approved treatment.
Executive Summary
- Remix Therapeutics will use a scientific conference presentation to reinforce clinical data it has already disclosed for its oral MYB-targeted therapy in a Phase 1/2 trial, rather than to unveil new results.
- The company previously reported a response rate and disease-control result from a small biomarker-selected cohort in a cancer that currently has no approved systemic treatment, giving the update a concrete evidentiary base rather than a purely promotional one.
- Enrollment has grown toward the trial's target and the primary completion date has moved out considerably, a combination that shifts the real test of durability further into 2027.
- The trial stands alone as the only Phase 1 or later program targeting this specific mechanism in this cancer, with the nearest scientific parallel found in a different modality and different tumor type rather than a direct rival.
The presentation
Remix Therapeutics said Chief Executive Officer Peter Smith will present a corporate update on REM-422, the company's oral MYB mRNA degrader, at the AACR Drug Discovery and Development Conference in Boston on July 24, 2026. Smith said the company would discuss "the clinical activity, durability of response and favorable safety results observed to date" in patients with MYB-driven cancers, including adenoid cystic carcinoma (ACC). The presentation is a conference update rather than a new data disclosure: Remix already reported the underlying results in a May 2026 release tied to the same trial, NCT06118086. Remix+1Remix Therapeutics to Present at AACR Drug Discovery and Development ConferenceJul 16, 2026Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic CarcinomaNCT06118086
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
The result behind it
In the recommended Phase 2 dose (RP2D) biomarker-positive cohort of the ARIA study, REM-422 produced an overall response rate of 43% (3 of 7 patients), with disease control in all seven and responses lasting more than a year. The trial reported no dose-limiting toxicities and mostly grade 1-2 treatment-related adverse events at the RP2D. ACC has no approved treatment options, and prior approaches including chemotherapy, kinase inhibitors and immunotherapy have shown modest or disappointing results in the disease. The FDA has granted REM-422 Orphan Drug and Fast Track designations for ACC. RemixRemix Therapeutics to Present at AACR Drug Discovery and Development ConferenceJul 16, 2026
The trial's shifting timeline
NCT06118086 is an open-label, non-randomized Phase 1/2 study testing an oral formulation of REM-422 in patients with recurrent, metastatic or unresectable ACC, with a Dose Escalation phase to find the maximum tolerated dose and a Confirmatory Cohort restricted to MYB poison-exon biomarker-positive tumors. Enrollment has grown from 65 to 100 to a current target of 125 patients as the trial expanded. The primary completion date has moved twice, from June 2025 to June 2026 and then to September 2027, a cumulative delay of about 16 months from the most recent guided date. The trial remains recruiting across sites in the United States and France. NCT06118086Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic CarcinomaNCT06118086
Where it sits competitively
No other industry trial targets MYB mRNA in adenoid cystic carcinoma, and REM-422's own trial is the only Phase 1-or-later program in this target-indication pairing. Other ACC programs test unrelated mechanisms, including an HDAC inhibitor from HitGen and a VEGFR2 inhibitor from Elevar Therapeutics, none of which shares REM-422's biology. The nearest mechanistic parallel for RNA-targeted degradation is CureVac's CV8102, an RNA therapy tested in cutaneous melanoma rather than ACC, underscoring that REM-422's mRNA-degradation approach has no direct precedent within this tumor type. Given that no mechanism has yet reached late-stage testing in ACC, the result that would extend the current signal is a Confirmatory Cohort readout showing the response rate and durability hold as the biomarker-positive population grows beyond the initial seven-patient group.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.